retatrutide triple agonist glp-1 gip glucagon phase 2 obesity is gaining attention in metabolic research for its activity on GIP, GLP-1, and receptors. In this carousel, we summarize recent clinical study findings related to weight management, type Difference between tirzepatide and retatrutide:
Description
AF, atrial fibrillation

Around 20-25% of the weight lost on retatrutide is muscle and bone rather than fat, similar to other drugs in this family
Prioritizing 7 to 9 hours of quality sleep supports cardiovascular adaptation

Postgrad Med 2014;126:6072

Overall, these results suggest that GLP-1 may regulate 3T3-L1 adipogenesis through the Akt signaling pathway

BMC Pharmacol
